at www.tipranks.com (Thu, 14-May 8:20 AM)
at www.tipranks.com (Thu, 14-May 5:20 AM)
Altimmune outlines PERFORMA Phase III MASH start in 2H 2026 and cash runway to 2029 52-week readout
at seekingalpha.com (Thu, 14-May 12:41 AM)
Altimmune Earnings Call: Cash Boost and Phase III Push
at www.tipranks.com (Wed, 13-May 8:47 PM)
Analysts Conflicted on These Healthcare Names: Altimmune (ALT) and Acurx Pharmaceuticals (ACXP)
at www.tipranks.com (Wed, 13-May 2:20 PM)
Altimmune GAAP EPS of -$0.18 beats by $0.07
at seekingalpha.com (Wed, 13-May 7:32 AM)